# Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

> **NCT06095583** · PHASE3 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 756 (estimated)

## Conditions studied

- Limited-stage Small Cell Lung Cancer (LS-SCLC)

## Interventions

- **DRUG:** Tifcemalimab injection
- **DRUG:** toripalimab injection
- **DRUG:** Placebo for Tifcemalimab
- **DRUG:** Placebo for toripalimab

## Key facts

- **NCT ID:** NCT06095583
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 756 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095583, "Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06095583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*